• The technology described in this briefing is DyeVert. It is intended to reduce the amount of contrast media given during coronary and peripheral angiographies.

  • The innovative aspects are that DyeVert could reduce contrast media given to a patient, whilst maintaining image quality. This aims to reduce the incidence of contrast-induced acute kidney injury (CI‑AKI).

  • The intended place in therapy would be with current coronary and peripheral angiography equipment in people at risk of AKI, such as patients with moderate to severe chronic kidney disease, diabetes, older age, or heart failure.

  • The main points from the evidence summarised in this briefing are from 6 studies: 2 randomised trials, 2 prospective non-comparative studies and 2 retrospective non-comparative studies. Included studies involved 381 adult patients, 274 of whom had DyeVert in a secondary care setting. The studies showed a reduction in the amount of contrast media given to the patient when DyeVert was used.

  • Key uncertainties around the evidence are that evidence about how DyeVert effects the incidence of CI‑AKI is limited. Most of the evidence is observational data and evidence with comparator arms is limited to single-site studies. Also, there is no published UK evidence.

  • The cost of DyeVert system disposable components is £350 (exclusive of VAT) per patient. The reusable monitor is included in the cost of the first set of disposable components. The resource impact could be lower if DyeVert reduced the incidence and the number of adverse events associated with AKI. There is some evidence to support this but it is limited.